New hope for Hard-to-Treat cancers: experimental drug combo enters human trials

NCT ID NCT03843359

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a first-in-human trial, so the drug's effectiveness is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bites and Stings neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site

Houston, Texas, 77030, United States
GSK Investigational Site

Melbourne, Victoria, 3000, Australia
GSK Investigational Site

Toronto, Ontario, M5G 1Z9, Canada
GSK Investigational Site

Bordeaux, 33076, France
GSK Investigational Site

Villejuif, 94805, France
GSK Investigational Site

Tokyo, 104-0045, Japan
GSK Investigational Site

Tokyo, 135-8550, Japan
GSK Investigational Site

Amsterdam, 1066 CX, Netherlands
GSK Investigational Site

Amsterdam, 1081 HV, Netherlands
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28050, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.